-
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
LancetOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363.
DiabetesSanda S, Greenbaum CJ -
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes.
DiabetesGreenbaum CJ, Atkinson MA -
Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes.
Clinical ImmunologySanda S, Bollyky J, Standifer N, Nepom GT, Hamerman JA, Greenbaum CJ -
Prediction and pathogenesis in type 1 diabetes.
ImmunityZiegler AG, Nepom GT -
Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium.
Clinical TrialsHall MA, King NM, Perdue LH, Hilner JE, Akolkar B, Greenbaum CJ, McKeon C, T1DGC. -
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Clinical ImmunologyHerold KC, Gitelman S, Greenbaum CJ, Puck J, Hagopian WA, Gottlieb PA, Sayre PH, Bianchine PJ, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group. -
Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.
European Journal of ImmunologyLong SA, Walker MR, Rieck M, James EA, Kwok WW, Sanda S, Pihoker C, Nepom GT, Buckner JH -
Type 1 Diabetes TrialNet--an international collaborative clinical trials network.
Annals of the New York Academy of SciencesSkyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study Group. -
Low-affinity major histocompatibility complex-binding peptides in type 1 diabetes.
DiabetesJames EA, Kwok WW -
Role of insulin resistance in predicting progression to type 1 diabetes.
Diabetes CareXu P, Cuthbertson D, Greenbaum CJ, Palmer JP, Krischer JP, Diabetes Prevention Trial Type 1 Study Group. -
Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion.
DiabetesHan CY, Subramanian S, Chan CK, Omer M, Chiba T, Wight TN, Chait A -
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
The Journal of Clinical Endocrinology and MetabolismBollyky J, Greenbaum CJ -
Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.
The Journal of Clinical Endocrinology and MetabolismRedondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum CJ, Palmer JP, Cuthbertson DD, Eisenbarth GS, Krischer JP, Schatz DA, Diabetes Prevention Trial Type 1 Study Group. -
Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo.
Journal of ImmunologyWeber SE, Harbertson J, Godebu E, Mros GA, Padrick RC, Carson BD, Ziegler SF, Bradley LM
